Valley Brook Capital Group Inc. Has $764,000 Stock Position in Eli Lilly and Company (NYSE:LLY)

Valley Brook Capital Group Inc. boosted its stake in Eli Lilly and Company (NYSE:LLY) by 3.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,311 shares of the company’s stock after purchasing an additional 40 shares during the quarter. Valley Brook Capital Group Inc.’s holdings in Eli Lilly and Company were worth $764,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. International Assets Investment Management LLC boosted its stake in Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after buying an additional 7,330,815 shares in the last quarter. Sapient Capital LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $682,139,000. J.P. Morgan Private Wealth Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at approximately $435,736,000. Vanguard Group Inc. increased its position in Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Eli Lilly and Company by 24.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock valued at $1,778,362,000 after purchasing an additional 645,473 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 2.8 %

NYSE:LLY traded down $20.94 during trading hours on Friday, reaching $734.97. The company had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. Eli Lilly and Company has a twelve month low of $419.80 and a twelve month high of $800.78. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a P/E/G ratio of 1.46 and a beta of 0.37. The business’s 50-day simple moving average is $761.06 and its two-hundred day simple moving average is $672.28.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period last year, the business posted $1.62 EPS. On average, equities analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. Citigroup upped their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research report on Wednesday, February 21st. Barclays boosted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.